Depression in pregnancy: time to stop terrifying pregnant women.
Recent studies have powerfully demonstrated that women with depression, whether treated with SSRIs or skip treatment, report double risk of cardiovascular malformations. Yet, physicians and epidemiologists continue to terrify women who are at serious life threatening risks if not treated pharmacologically, with non evidence-based information. This paper calls for immediate stop of such practice.
The Motherisk Program, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, Canada. gkoren@sickkids.ca
Gideon
G
Koren
D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D005239:Fear; D005260:Female; D006330:Heart Defects, Congenital / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors